Latent Tuberculosis
Mostrando 13-24 de 102 artigos, teses e dissertações.
-
13. POTENCIAIS ALVOS MOLECULARES PARA O DESENVOLVIMENTO DE NOVOS FÁRMACOS ANTITUBERCULOSE
Tuberculosis (TB) is an infectious disease caused by mycobacteria from the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization (WHO) aims to reduce the number of TB cases worldwide in the coming years. Nevertheless, the increasing number of multidrug-resistant (MDR-TB) and extensive-drug resistance (XDR-TB) strains,
Quím. Nova. Publicado em: 2017-06
-
14. Imbalance of Th17 and Treg in peripheral blood mononuclear cells of active tuberculosis patients
Abstract Objective: Maintaining a right balance between Th17 and Treg might be critical to the immunopathogenesis of active tuberculosis (TB). This study aimed to assess whether the Th17/Treg balance is altered in active TB patients. Methods: 250 study subjects (90 active TB patients, 80 latent TB subjects, and 80 healthy controls) were recruited for the s
Braz J Infect Dis. Publicado em: 2017-03
-
15. Concordance between IFNγ gene +874 A/T polymorphism and interferon-γ expression in a TB-endemic indigenous setting
Abstract INTRODUCTION: Interferon-γ (IFN-γ) plays a crucial role in resistance to mycobacterial diseases; accordingly, variants of the gene encoding this cytokine may be associated with elevated risk of contracting pulmonary tuberculosis (TB). METHODS: Blood samples were collected from 135 Warao indigenous individuals with newly diagnosed sputum culture
Rev. Soc. Bras. Med. Trop.. Publicado em: 2017-03
-
16. Prevalence and factors associated with latent tuberculosis infection in an indigenous population in the Brazilian Amazon
Abstract: INTRODUCTION Recent studies have shown a high incidence and prevalence of latent tuberculosis infection (LTBI) in indigenous populations around the World. We aimed to estimate the prevalence and annual risk of infection (ARI) as well as to identify factors associated with LTBI in an indigenous population from the Brazilian Amazon. METHODS We cond
Rev. Soc. Bras. Med. Trop.. Publicado em: 2016-08
-
17. Insilico Analysis of Phytoconstituents from Allium sativum as Potential Inhibitors of Inha in Mycobacterium tuberculosis
ABSTRACT Tuberculosis is leading cause of death among the global bacterial infections. The main causative for tuberculosis is Mycobacterium tuberculosis, which will survive in its host human being for decades in latent or chronic levels. In addition, the late multidrug resistance at a disturbing rate accompanies the appearance of tuberculosis. The quick spre
Braz. arch. biol. technol.. Publicado em: 27/06/2016
-
18. High incidence of tuberculosis in patients treated for hepatitis C chronic infection
Abstract Brazil is one of the 22 countries that concentrates 80% of global tuberculosis cases concomitantly to a large number of hepatitis C carriers and some epidemiological risk scenarios are coincident for both diseases. We analyzed tuberculosis cases that occurred during α-interferon-based therapy for hepatitis C in reference centers in Brazil between 2
Braz J Infect Dis. Publicado em: 2016-04
-
19. Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil
Abstract Setting Patients HIV+ attending in a reference clinic, Southern Brazil. Objective To compare the interferon-gamma-release assay (IGRA – QuantiFERON® TB Gold In-Tube) with the tuberculin skin test (TST – PPD-Rt 23) for latent tuberculosis infection (LTBI) in patients with HIV. Design Cohort study. Patients were simultaneously submitted to the
Braz J Infect Dis. Publicado em: 2016-02
-
20. Diagnosis of latent Mycobacterium tuberculosis infection: tuberculin test versus interferon-gamma release
Abstract: INTRODUCTION: The treatment of individuals with active tuberculosis (TB) and the identification and treatment of latent tuberculosis infection (LTBI) contacts are the two most important strategies for the control of TB. The objective of this study was compare the performance of tuberculin skin testing (TST) with QuantiFERON-TB Gold In TUBE(r) in
Rev. Soc. Bras. Med. Trop.. Publicado em: 2015-12
-
21. Challenging Mycobacterium tuberculosi s dormancy mechanisms and their immunodiagnostic potential
ABSTRACT Mycobacterium tuberculosis is the etiologic agent of tuberculosis, one of the world's greatest cause of morbidity and mortality due to infectious disease. Many evolutionary mechanisms have contributed to its high level of adaptation as a host pathogen. Prior to become dormant, a group of about 50 genes related to metabolic changes are transcribed by
Braz J Infect Dis. Publicado em: 2015-12
-
22. Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline - A longitudinal analysis after using TNFa blockers
Several studies point to the increased risk of reactivation of latent tuberculosis infection (LTBI) in patients with chronic inflammatory arthritis (CIAs) after using tumour necrosis factor (TNF)a blockers. To study the incidence of active mycobacterial infections (aMI) in patients starting TNFa blockers, 262 patients were included in this study: 109 with rh
Mem. Inst. Oswaldo Cruz. Publicado em: 2015-11
-
23. Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil
Rev. Soc. Bras. Med. Trop.. Publicado em: 2015-10
-
24. Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence
AbstractLatent tuberculosis infection (LTBI) and human immunodeficiency virus (HIV)-coinfection are challenges in the control of tuberculosis transmission. We aimed to assess and summarize evidence available in the literature regarding the treatment of LTBI in both the general and HIV-positive population, in order to support decision making by the Brazilian
Rev. Soc. Bras. Med. Trop.. Publicado em: 2015-10